Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-08-11 Disposition | 2023-08-11 4:10 pm | N/A N/A | Sigilon Therapeutics Inc. | SGTX | Pontes Josias CHIEF FINANCIAL OFFICER | 3,504 | $0 | 0 (Direct) | View |
| 2023-08-11 Disposition | 2023-08-11 4:10 pm | N/A 2033-02-27 | Sigilon Therapeutics Inc. | SGTX | Pontes Josias CHIEF FINANCIAL OFFICER | 10,767 | $0.75 | 0 (Direct) | View |
| 2023-07-21 Exercise | 2023-07-24 7:45 pm | N/A N/A | Sigilon Therapeutics Inc. | SGTX | Pontes Josias CHIEF FINANCIAL OFFICER | 1,444 | $19.24 | 6,425 (Direct) | View |
| 2023-07-21 Exercise | 2023-07-24 7:45 pm | N/A 2032-02-17 | Sigilon Therapeutics Inc. | SGTX | Pontes Josias CHIEF FINANCIAL OFFICER | 1,444 | $0 | 6,425 (Direct) | View |
| 2023-02-28 Option Award | 2023-03-01 4:41 pm | N/A 2033-02-27 | Sigilon Therapeutics Inc. | SGTX | Pontes Josias CHIEF FINANCIAL OFFICER | 140,000 | $0 | 140,000 (Direct) | View |
| 2022-02-18 Option Award | 2022-02-22 5:00 pm | N/A 2032-02-17 | Sigilon Therapeutics Inc. | SGTX | Pontes Josias ACTING CHIEF FINANCIAL OFFICE | 60,000 | $1.48 | 60,000 (Direct) | View |
| 2022-01-03 Option Award | 2022-01-04 4:16 pm | N/A 2032-01-02 | Sigilon Therapeutics Inc. | SGTX | Pontes Josias VP, HEAD OF FINANCE | 65,000 | $3.03 | 65,000 (Direct) | View |
| 2021-09-30 Option Award | 2021-10-04 4:15 pm | N/A N/A | Sigilon Therapeutics Inc. | SGTX | Pontes Josias VP, HEAD OF FINANCE | 11,500 | $0 | 13,339 (Direct) | View |
Ownership | 2021-06-21 4:20 pm | N/A N/A | Sigilon Therapeutics Inc. | SGTX | Pontes Josias VP, Head of Finance | 0 | $0 | 93,154 (Direct) | View |